Dawakof is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Dawakof stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Dawakof stimulates production of phospholipids of surfactant by alveolar cells. Dawakof has anti-inflammatory properties. In patients with COPD, it improves airway patency. Beside these, Dawakof also exhibits anti-oxidant activity. Long-term use is possible because of the good tolerability of the preparation.
